Adithya Cattamanchi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5531722/publications.pdf

Version: 2024-02-01

99 papers	4,059 citations	201674 27 h-index	128289 60 g-index
110 all docs	110 docs citations	110 times ranked	5065 citing authors

#	Article	IF	Citations
1	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 2016, 63, e147-e195.	5.8	916
2	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	5.6	282
3	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 230-238.	2.1	260
4	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
5	Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. Annual Review of Public Health, 2018, 39, 5-25.	17.4	187
6	Clinical Characteristics and Treatment Outcomes of Patients with Isoniazidâ€Monoresistant Tuberculosis. Clinical Infectious Diseases, 2009, 48, 179-185.	5.8	98
7	Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infectious Diseases, The, 2017, 17, 1285-1292.	9.1	96
8	Strategies for implementing implementation science: a methodological overview. Emergency Medicine Journal, 2016, 33, 660-664.	1.0	92
9	Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. American Journal of Tropical Medicine and Hygiene, 2003, 68, 133-9.	1.4	88
10	Transcriptional Adaptation of Drug-tolerant‹i›Mycobacterium tuberculosis‹/i›During Treatment of Human Tuberculosis. Journal of Infectious Diseases, 2015, 212, 990-998.	4.0	82
11	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	10.7	80
12	Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach. Implementation Science, 2017, 12, 33.	6.9	77
13	Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infectious Diseases, 2009, 9, 53.	2.9	71
14	Impact of Xpert MTB/RIF Testing on Tuberculosis Management and Outcomes in Hospitalized Patients in Uganda. PLoS ONE, 2012, 7, e48599.	2.5	68
15	Health worker perspectives on barriers to delivery of routine tuberculosis diagnostic evaluation services in Uganda: a qualitative study to guide clinic-based interventions. BMC Health Services Research, 2015, 15, 10.	2.2	66
16	Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation. Journal of Clinical Microbiology, 2016, 54, 274-282.	3.9	55
17	The Lung Microbiome of Ugandan HIV-Infected Pneumonia Patients Is Compositionally and Functionally Distinct from That of San Franciscan Patients. PLoS ONE, 2014, 9, e95726.	2.5	53
18	Addressing health disparities through implementation scienceâ€”a need to integrate an equity lens from the outset. Implementation Science, 2022, 17, 13.	6.9	51

#	Article	IF	Citations
19	Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases, 2019, 19, 268.	2.9	48
20	Integrated Strategies to Optimize Sputum Smear Microscopy. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 547-551.	5.6	42
21	Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infectious Diseases, 2016, 3, ofw068.	0.9	42
22	Impact of GeneXpert MTB/RIF Assay on Triage of Respiratory Isolation Rooms for Inpatients With Presumed Tuberculosis: A Hypothetical Trial. Clinical Infectious Diseases, 2014, 59, 1353-1360.	5.8	40
23	Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. PLoS ONE, 2017, 12, e0180572.	2.5	37
24	Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 643-650.	5.6	36
25	Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infectious Diseases, 2010, 10, 75.	2.9	33
26	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. Journal of Infectious Diseases, 2019, 220, S116-S125.	4.0	33
27	Investigation of Preanalytical Variables Impacting Pathogen Cell-Free DNA in Blood and Urine. Journal of Clinical Microbiology, 2019, 57, .	3.9	33
28	Characterization of oral swab samples for diagnosis of pulmonary tuberculosis. PLoS ONE, 2021, 16, e0251422.	2.5	31
29	Digital adherence technology for tuberculosis treatment supervision: AÂstepped-wedge cluster-randomized trialÂin Uganda. PLoS Medicine, 2021, 18, e1003628.	8.4	31
30	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. Lancet Infectious Diseases, The, 2022, 22, 507-518.	9.1	28
31	Detailed Analysis of the Radiographic Presentation of Mycobacterium kansasii Lung Disease in Patients With HIV Infection. Chest, 2008, 133, 875-880.	0.8	27
32	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. Scientific Reports, 2016, 6, 30781.	3.3	27
33	Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda. PLoS ONE, 2017, 12, e0180122.	2.5	27
34	Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECo) study protocol. Trials, 2018, 19, 571.	1.6	26
35	Theory-Informed Interventions to Improve the Quality of Tuberculosis Evaluation at Ugandan Health Centers: A Quasi-Experimental Study. PLoS ONE, 2015, 10, e0132573.	2.5	24
36	Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis. PLoS ONE, 2019, 14, e0214161.	2.5	24

#	Article	IF	Citations
37	Poor Performance of Universal Sample Processing Method for Diagnosis of Pulmonary Tuberculosis by Smear Microscopy and Culture in Uganda. Journal of Clinical Microbiology, 2008, 46, 3325-3329.	3.9	23
38	Challenges with scale-up of GeneXpert MTB/RIFÂ® in Uganda: a health systems perspective. BMC Health Services Research, 2020, 20, 162.	2.2	23
39	A Clinical Predictor Score for 30-Day Mortality among HIV-Infected Adults Hospitalized with Pneumonia in Uganda. PLoS ONE, 2015, 10, e0126591.	2.5	23
40	Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital. JAMA Internal Medicine, 2018, 178, 1380.	5.1	22
41	Improving the cascade of global tuberculosis care: moving from the â€œwhatâ€•to the â€œhowâ€•of quality improvement. Lancet Infectious Diseases, The, 2019, 19, e437-e443.	9.1	22
42	Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010â€“2015. BMC Public Health, 2019, 19, 446.	2.9	21
43	A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2019, 69, 77-83.	5.8	20
44	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 564-571.	5.6	20
45	Bronchoalveolar Lavage Enzyme-Linked Immunospot for Diagnosis of Smear-Negative Tuberculosis in HIV-Infected Patients. PLoS ONE, 2012, 7, e39838.	2.5	17
46	Tobacco and tuberculosis: could we improve tuberculosis outcomes by helping patients to stop smoking?. European Respiratory Journal, 2015, 45, 583-585.	6.7	17
47	Feasibility of a short message service (SMS) intervention to deliver tuberculosis testing results in peri-urban and rural Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 16, 100110.	1.3	15
48	Outlook for tuberculosis elimination in California: An individual-based stochastic model. PLoS ONE, 2019, 14, e0214532.	2.5	15
49	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). Implementation Science, 2020, 15, 24.	6.9	14
50	Barriers to the Use of Clinical Decision Support for the Evaluation of Pulmonary Embolism: Qualitative Interview Study. JMIR Human Factors, 2021, 8, e25046.	2.0	13
51	Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. JMIR Formative Research, 2020, 4, e19270.	1.4	13
52	Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. New England Journal of Medicine, 2021, 385, 2441-2450.	27.0	13
53	Investigating Barriers to Tuberculosis Evaluation in Uganda Using Geographic Information Systems. American Journal of Tropical Medicine and Hygiene, 2015, 93, 733-738.	1.4	12
54	Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 18, 100136.	1.3	12

#	Article	IF	Citations
55	Changing Clinician Behavior When Less Is More. JAMA Internal Medicine, 2015, 175, 1921.	5.1	11
56	Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. BMC Public Health, 2016, 16, 875.	2.9	11
57	Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV. PLoS ONE, 2018, 13, e0206119.	2.5	11
58	Toward Comprehensive Plasma Proteomics by Orthogonal Protease Digestion. Journal of Proteome Research, 2021, 20, 4031-4040.	3.7	11
59	Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ Open, 2020, 10, e039895.	1.9	11
60	Estimating the effect of pretreatment loss to follow up on TB associated mortality at public health facilities in Uganda. PLoS ONE, 2020, 15, e0241611.	2.5	11
61	Unusual Radiographic Presentation of Pneumocystis Pneumonia in a Patient with AIDS. Case Reports in Infectious Diseases, 2017, 2017, 1-6.	0.5	10
62	Brief Report: â€œGive Me Some Timeâ€ Facilitators of and Barriers to Uptake of Home-Based HIV Testing During Household Contact Investigation for Tuberculosis in Kampala, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 400-404.	2.1	10
63	Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India. Infectious Diseases of Poverty, 2020, 9, 144.	3.7	10
64	Assessing the Quality of Tuberculosis Evaluation for Children with Prolonged Cough Presenting to Routine Community Health Care Settings in Rural Uganda. PLoS ONE, 2014, 9, e105935.	2.5	9
65	Seasonality of childhood tuberculosis cases in Kampala, Uganda, 2010-2015. PLoS ONE, 2019, 14, e0214555.	2.5	9
66	Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy. Aids, 2019, 33, 895-902.	2.2	9
67	A Prospective Evaluation of Xpert MTB/RIF Ultra for Childhood Pulmonary Tuberculosis in Uganda. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 586-592.	1.3	9
68	Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation Science, 2020, 15, 65.	6.9	8
69	Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. Scientific Reports, 2020, 10, 13944.	3.3	8
70	Evaluation of multi-antigen serological screening for active tuberculosis among people living with HIV. PLoS ONE, 2020, 15, e0234130.	2.5	8
71	Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS ONE, 2021, 16, e0246113.	2.5	8
72	Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda. Value in Health, 2022, 25, 924-930.	0.3	8

#	Article	IF	Citations
73	Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. BMJ Global Health, 2016, 1, e000064.	4.7	7
74	The University of California San Francisco (UCSF) Training Program in Implementation Science: Program Experiences and Outcomes. Frontiers in Public Health, 2020, 8, 94.	2.7	7
75	Whole-genome sequencing and single nucleotide polymorphisms in multidrug-resistant clinical isolates of Mycobacterium tuberculosis from the Philippines. Journal of Global Antimicrobial Resistance, 2018, 15, 239-245.	2.2	6
76	Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 15, 100099.	1.3	6
77	Brief Report: Yield and Efficiency of Intensified Tuberculosis Case-Finding Algorithms in 2 High-Risk HIV Subgroups in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 416-420.	2.1	6
78	Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Ugandaâ€”patient and health worker perspectives. Implementation Science Communications, 2021, 2, 71.	2.2	6
79	Patient Perspectives and Willingness to Accept Incentives for Tuberculosis Diagnostic Evaluation in Uganda. Value in Health Regional Issues, 2021, 25, 48-56.	1.2	6
80	Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100184.	1.3	6
81	Completion of isoniazidâ€“rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectivenessâ€“implementation randomized trial. PLoS Medicine, 2021, 18, e1003875.	8.4	6
82	Patient and health system factors associated with pretreatment loss to follow up among patients diagnosed with tuberculosis using XpertÂ® MTB/RIF testing in Uganda. BMC Public Health, 2020, 20, 1855.	2.9	4
83	Implementing pediatric inpatient asthma pathways. Journal of Asthma, 2021, 58, 893-902.	1.7	4
84	Where will it end? Pathways to care and catastrophic costs following negative TB evaluation in Uganda. PLoS ONE, 2021, 16, e0253927.	2.5	4
85	Validating novel diagnostic assays for tuberculosis in the context of existing tools. The Lancet Global Health, 2021, 9, e1209.	6.3	4
86	Impact of shelter-in-place orders on TB case notifications and mortality in the Philippines during the COVID-19 pandemic. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 25, 100282.	1.3	4
87	Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda. Implementation Science Communications, 2022, 3, 9.	2.2	4
88	A Transcriptional Signature for Active TB: Have We Found the Needle in the Haystack?. PLoS Medicine, 2013, 10, e1001539.	8.4	3
89	Field evaluation of a prototype tuberculosis lipoarabinomannan lateral flow assay on HIV-positive and HIV-negative patients. PLoS ONE, 2021, 16, e0254156.	2.5	3
90	OUP accepted manuscript. Journal of the Pediatric Infectious Diseases Society, 2022, , .	1.3	3

#	Article	IF	Citations
91	Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics, 2019, 9, 56.	2.6	2
92	Impact of hematocrit on point-of-care C-reactive protein-based tuberculosis screening among people living with HIV initiating antiretroviral therapy in Uganda. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115281.	1.8	2
93	Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Research, 2019, 4, 173.	1.8	2
94	Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Research, 2019, 4, 173.	1.8	2
95	Perceptions, preferences, and experiences of tuberculosis education and counselling among patients and providers in Kampala, Uganda: A qualitative study. Global Public Health, 2022, 17, 2911-2928.	2.0	2
96	Predictors of Quality Improvement in Pediatric Asthma Care. Hospital Pediatrics, 2020, 10, 1114-1119.	1.3	1
97	Design and execution of a public randomization ceremony to enhance stakeholder engagement within a cluster randomized trial to improve tuberculosis diagnosis in Uganda. Contemporary Clinical Trials Communications, 2021, 22, 100707.	1.1	1
98	Diabetes prevention in the Caribbean using Lifestyle Intervention and Metformin Escalation (LIME): Protocol for a hybrid Type-1 effectiveness-implementation trial using a quasi-experimental study design. Contemporary Clinical Trials Communications, 2021, 22, 100750.	1.1	1
99	In vitro immunomodulation for enhancing T cellâ€“based diagnosis of Mycobacterium tuberculosis infection. Diagnostic Microbiology and Infectious Disease, 2015, 83, 41-45.	1.8	0